

08 OCT 2004

Nonspecific Protection Against Lethal Influenza Challenge





FIGURE 1

Clinical Symptoms Following Intranasal Administration of L-Seryl AGPs




Numbers in parenthesis represent the length of the secondary fatty acid chains.

FIGURE 2



08 OCT 2004



Clinical Symptoms Following L-Seryl AGPs Monotherapy and Influenza Challenge





Numbers in parenthesis represent the percent protection following lethal challenge.



FIGURE 3



*Fig. 4A**Fig. 4B*



*Fig. 4C**Fig. 4D*

*Fig. 5A**Fig. 5B*



08 OCT 2004



*Fig. 5C**Fig. 5D*

*Fig. 6A**Fig. 6B*



*Fig. 6C**Fig. 6D*



10/14



*Fig. 7A**Fig. 7B*

*Fig. 8A**Fig. 8B*

12/14

*Fig. 8C**Fig. 8D*

*Fig. 9A**Fig. 9B*

*Fig. 9C**Fig. 9D*